Skip to main content
. Author manuscript; available in PMC: 2011 Apr 27.
Published in final edited form as: Br J Haematol. 2008 Nov 22;144(3):388–394. doi: 10.1111/j.1365-2141.2008.07461.x

Table II.

Treatment-related mortality by therapy received

CDD Genotype TRM from study entry N= Post induction TRM N= Post randomization TRM N=293 IDA-DCTER Total Cytarabine 3200 mg/m2 N=137 IDA-FLAG Total Cytarabine 9190 mg/m2 N=135
AA 15 ±5% 12 ±5% 6.9% ± 4.2% 8.2% ± 6.4% 6.3% ± 6.1%
AC 18 ±6% 13 ±6% 4.8% ± 4.2% 4.3% ± 6.0% 5.9% ± 6.7%
CC 20 ±12% 20 ±12% 17.1% ± 12.7% 15.4% ± 20% 23.5% ± 20.6%
P-value 0.59 0.55 0.05 0.39 0.06